ATEM (Alvesco Non-interventional Study)

This study has been completed.
Sponsor:
Information provided by:
Nycomed: A Takeda Company
ClinicalTrials.gov Identifier:
NCT01147224
First received: June 17, 2010
Last updated: May 4, 2012
Last verified: May 2012
  Purpose

The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season. Alvesco will be inhaled by a metered-dose inhaler. The study will provide further data on safety and tolerability of Alvesco .


Condition Intervention
Asthma
Allergy
Drug: Alvesco

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Alvesco for the Therapy of Persistent Asthma With or Without Allergic Component

Resource links provided by NLM:


Further study details as provided by Nycomed: A Takeda Company:

Primary Outcome Measures:
  • Treatment success with Alvesco [ Time Frame: after 3 months ] [ Designated as safety issue: No ]
    Pre-/ post comparison of FEV1, Quality of life, Patient Questionnaire


Secondary Outcome Measures:
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: after 3 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 400
Study Start Date: March 2010
Study Completion Date: August 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
ATEM
A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
Drug: Alvesco
This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Other Name: Ciclesonide

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Outpatients

Criteria

Main Inclusion Criteria:

  • Asthma with or without allergic components

Main Exclusion Criteria:

  • Hypersensitive to compounds of Alvesco
  • Other criteria as defined in the Summary of Product Characteristics, Chapter 4.3
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01147224

  Hide Study Locations
Locations
Austria
Nycomed Pharma GmbH
Amstetten, Austria, 3300
Nycomed Pharma GmbH
Baden, Austria, 2500
Nycomed Pharma GmbH
Bludenz, Austria, 6700
Nycomed Pharma GmbH
Braunau, Austria, 5280
Nycomed Pharma GmbH
Bregenz, Austria, 6900
Nycomed Pharma GmbH
Böhlerwerk, Austria, 3333
Nycomed Pharma GmbH
Dornbirn, Austria, 6850
Nycomed Pharma GmbH
Enns, Austria, 4470
Nycomed Pharma GmbH
Feldbach, Austria, 8330
Nycomed Pharma GmbH
Feldkirch, Austria, 6800
Nycomed Pharma GmbH
Furth, Austria, 3511
Nycomed Pharma GmbH
Gföhl, Austria, 3542
Nycomed Pharma GmbH
Gr. Siegharts, Austria, 3812
Nycomed Pharma GmbH
Graz, Austria, 8010
Nycomed Pharma GmbH
Graz, Austria, 8036
Nycomed Pharma GmbH
Graz, Austria, 8042
Nycomed Pharma GmbH
Graz, Austria, 8020
Nycomed Pharma GmbH
Graz-Gösting, Austria, 8051
Nycomed Pharma GmbH
Groß Gerungs, Austria, 3920
Nycomed Pharma GmbH
Gunskirchen, Austria, 4623
Nycomed Pharma GmbH
Güssing, Austria, 7540
Nycomed Pharma GmbH
Haag, Austria, 4680
Nycomed Pharma GmbH
Hall in Tirol, Austria, 6060
Nycomed Pharma GmbH
Hallein, Austria, 5400
Nycomed Pharma GmbH
Hartberg, Austria, 8230
Nycomed Pharma GmbH
Herzogenburg, Austria, 3130
Nycomed Pharma GmbH
Innsbruck, Austria, 6020
Nycomed Pharma GmbH
Judenburg, Austria, 8750
Nycomed Pharma GmbH
Kaltenbach, Austria, 6272
Nycomed Pharma GmbH
Kirchdorf and der Krems, Austria, 4560
Nycomed Pharma GmbH
Kitzbühel, Austria, 6370
Nycomed Pharma GmbH
Klein-Pöchlam, Austria, 3660
Nycomed Pharma GmbH
Landeck, Austria, 6500
Nycomed Pharma GmbH
Leibnitz, Austria, 8430
Nycomed Pharma GmbH
Lenzing, Austria, 4860
Nycomed Pharma GmbH
Linz, Austria, 4030
Nycomed Pharma GmbH
Linz, Austria, 4040
Nycomed Pharma GmbH
Linz, Austria, 4020
Nycomed Pharma GmbH
Litschau, Austria, 3874
Nycomed Pharma GmbH
Mank, Austria, 3240
Nycomed Pharma GmbH
Melk, Austria, 3390
Nycomed Pharma GmbH
Mittersill, Austria, 5730
Nycomed Pharma GmbH
Munster, Austria, 6232
Nycomed Pharma GmbH
Mödling, Austria, 2340
Nycomed Pharma GmbH
Mühldorf, Austria, 3622
Nycomed Pharma GmbH
Neumarkt, Austria, 7461
Nycomed Pharma GmbH
Niederkreuzstetten, Austria, 2124
Nycomed Pharma GmbH
Pasching, Austria, 4061
Nycomed Pharma GmbH
Pinkafeld, Austria, 7423
Nycomed Pharma GmbH
Pucking, Austria, 4055
Nycomed Pharma GmbH
Salzburg, Austria, 5020
Nycomed Pharma GmbH
Schlüßlberg, Austria, 4707
Nycomed Pharma GmbH
Schwanenstadt, Austria, 4690
Nycomed Pharma GmbH
Schörfling, Austria, 4861
Nycomed Pharma GmbH
St. Johann i. Pg., Austria, 5600
Nycomed Pharma GmbH
St. Pölten, Austria, 3100
Nycomed Pharma GmbH
St.Georgen i.A., Austria, 4880
Nycomed Pharma GmbH
Steyr, Austria, 4400
Nycomed Pharma GmbH
Strallegg, Austria, 8192
Nycomed Pharma GmbH
Sulz, Austria, 6832
Nycomed Pharma GmbH
Thalheim bei Wels, Austria, 4600
Nycomed Pharma GmbH
Traisen, Austria, 3160
Nycomed Pharma GmbH
Traismauer, Austria, 3133
Nycomed Pharma GmbH
Voitsberg, Austria, 8570
Nycomed Pharma GmbH
Waidhofen/Thaya, Austria, 3830
Nycomed Pharma GmbH
Weitra, Austria, 3970
Nycomed Pharma GmbH
Wien, Austria, 1030
Nycomed Pharma GmbH
Wien, Austria, 1080
Nycomed Pharma GmbH
Wien, Austria, 1190
Nycomed Pharma GmbH
Wien, Austria, 1010
Nycomed Pharma GmbH
Wien, Austria, 1220
Nycomed Pharma GmbH
Wien, Austria, 1210
Nycomed Pharma GmbH
Wien, Austria, 1100
Nycomed Pharma GmbH
Wien, Austria, 1090
Nycomed Pharma GmbH
Wien, Austria, 1230
Nycomed Pharma GmbH
Wiener Neustadt, Austria, 2700
Nycomed Pharma GmbH
Wilhelmsburg, Austria, 3150
Nycomed Pharma GmbH
Wr. Neustadt, Austria, 2700
Nycomed Pharma GmbH
Yspertal, Austria, 3683
Nycomed Pharma GmbH
Zwettl, Austria, 3910
Sponsors and Collaborators
Nycomed: A Takeda Company
Investigators
Study Director: Ingrid Moll-Schüler, MD Nycomed Pharma GmbH
  More Information

No publications provided

Responsible Party: Dr. Ingrid Moll-Schüler, Nycomed Pharma GmbH
ClinicalTrials.gov Identifier: NCT01147224     History of Changes
Other Study ID Numbers: CL-9709-401-DE
Study First Received: June 17, 2010
Last Updated: May 4, 2012
Health Authority: Austria: Ethikkommission

Keywords provided by Nycomed: A Takeda Company:
Asthma
Allergy
Ciclesonide
Alvesco
Inhaled steroids

Additional relevant MeSH terms:
Hypersensitivity
Asthma
Immune System Diseases
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Ciclesonide
Anti-Allergic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 17, 2013